Outcome of Classic Hodgkin Lymphoma Treated with ABVD Regimen- A Single Center Experience
References
- Alaggio R, Amador C, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36(7):1720–48.
- Sehn LH. Introduction to a review series on Hodgkin lymphoma: change is here. Blood. 2018;131(15):1629–30.
- Moskowitz AJ. Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy. Hematology Am Soc Hematol Educ Program. 2018;2018(1):207–12.
- Cheson BD, Fisher RI, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non- Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–68.
- UNDP. Statistical Update 2018 2018 [Available from:
http://report2017.archive.s3-website-us-east-1.amazonaws.com . - Pan T, Zhang J, et al. Global burden and trends of hematologic malignancies based on Global Cancer Observatory 2022 and Global Burden of Disease 2021. Experimental Hematology & Oncology. 2025;14(1):98.
- Suttantapidok S, Kungwankiattichai S, et al. Treatment outcomes of ABVD in classical Hodgkin lymphoma patients from Thailand without procarbazine access. Sci Rep. 2025;15(1):22211.
- Mponda M, Kudowa E, et al. Safety, efficacy, and affordability of ABVD for Hodgkin lymphoma in Malawi: a prospective cohort study. EClinicalMedicine. 2024;69:102480.
- Campo E, Swerdlow SH, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–32.
- Swerdlow SH, editor WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues2017.
- Network NCC. Hodgkin Lymphoma (Version 2.2025) 2025 [Available from:
https://www.nccn.org/login?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf - Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med. 1998;339(21):1506–14.
- Cheson BD, Horning SJ, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.
- Tadmor T, Bari A, et al. Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients. Mayo Clin Proc. 2015;90(6):756–64.
- Marcheselli R, Bari A, et al. Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients. Hematol Oncol. 2017;35(4):561–6.
- Rueda Dominguez A, Alfaro Lizaso J, et al. SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma. Clin Transl Oncol. 2015;17(12):1005–13.
- Johnson P, Federico M, et al. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma. N Engl J Med. 2016;374(25):2419–29.
- Ali S, Basit A, et al. Chemotherapy alone or combined chemotherapy and involved field radiotherapy in favorable risk early-stage classical Hodgkin lymphoma-a 10 years experience. Pak J Med Sci. 2016;32(6):1408–13.
- Jacob LA, Begum T, et al. Clinical Profile and Outcome of Adult Classical Hodgkin’s Lymphoma: Real World Single Centre Experience. Indian J Hematol Blood Transfus. 2024;40(3):392–9.
- Iftikhar I, Abbas M, et al. Real-World Outcomes of PET-Adapted Treatment for Classic Hodgkin’s Lymphoma: A Study From a Single Tertiary Care Center. Cureus. 2025;17(5):e83836.
- Rose A, Grajales-Cruz A, et al. Classical Hodgkin Lymphoma: Clinicopathologic Features, Prognostic Factors, and Outcomes From a 28-Year Single Institutional Experience. Clin Lymphoma Myeloma Leuk. 2021;21(2):132–8.
- Wen Q, Ge J, et al. Real-world evidence of ABVD-like regimens compared with ABVD in classical Hodgkin lymphoma: a 10-year study from China. J Cancer Res Clin Oncol. 2023;149(7):3989–4003.
- Biasoli I, Castro N, et al. Treatment outcomes for Hodgkin lymphoma: First report from the Brazilian Prospective Registry. Hematol Oncol. 2018;36(1):189–95.
- DeBoer RJ, Shyirambere C, et al. Treatment of Hodgkin Lymphoma With ABVD Chemotherapy in Rural Rwanda: A Model for Cancer Care Delivery Implementation. JCO Glob Oncol. 2020;6: 1093–102.
- Bhurani D, Nair R, et al. Real-World Outcomes of Hodgkin Lymphoma: A Multi-Centric Registry From India. Front Oncol. 2021;11:799948.
- Shafi RG, Al-Mansour MM, et al. Hodgkin Lymphoma Outcome: A Retrospective Study from 3 Tertiary Centers in Saudi Arabia. Oncol Res Treat. 2017;40(5):288–92.
- Boo YL, Ting HSY, et al. Clinical features and treatment outcomes of Hodgkin lymphoma: A retrospective review in a Malaysian tertiary hospital. Blood Res. 2019;54(3):210–7.
- Cuccaro A, Bartolomei F, et al. Prognostic factors in hodgkin lymphoma. Mediterr J Hematol Infect Dis. 2014;6(1): e2014053.
- Cellini A, Cavarretta CA, et al. Baseline prognostic predictors in classical Hodgkin Lymphoma: a retrospective, single-center analysis on patients treated with PET/CT-guided ABVD. Front Oncol. 2024;14:1419118.
DOI: https://doi.org/10.2478/jcas-2026-0008 | Journal eISSN: 2411-989X
Language: English
Page range: 50 - 58
Published on: Jun 29, 2026
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Related subjects:
© 2026 Nouman Nawaz Ali, Madiha Noor, Natasha Ali, Mohammad Usman Shaikh, Salman Naseem Adil, published by Shakuat Khanum Memorial Cancer Hospital and Research Centre
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.